866-997-4948(US-Canada Toll Free)

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 54 Pages

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2017

Summary

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 16 molecules. Out of which approximately 16 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6 and 6 respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Renal Cell Carcinoma.

The latest report Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
- The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview 7
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development 19
Aurigene Discovery Technologies Ltd 19
BeiGene Ltd 19
Eli Lilly and Co 20
Enumeral Biomedical Holdings Inc 20
Incyte Corp 20
Interprotein Corp 21
Jounce Therapeutics Inc 21
Merus NV 22
Novartis AG 22
Sorrento Therapeutics Inc 23
Sutro Biopharma Inc 23
Tesaro Inc 24
Trellis Bioscience Inc 24
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles 25
BGBA-425 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Bispecific Monoclonal Antibody to Inhibit TIM3 for Oncology - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CA-170 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CA-327 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
ENUM-005 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
IMM-1802 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
LY-3321367 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
MCLA-134 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MGB-453 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Monoclonal Antibodies 3 to Inhibit TIM3 for Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Monoclonal Antibody to Inhibit TIM-3 for Oncology - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Monoclonal Antibody to Inhibit TIM3 for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
STI-600 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
TRL-6061 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
TSR-022 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products 44
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones 45
Featured News & Press Releases 45
Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017 45
Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress 46
May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting 46
Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170s Phase 1 Trial at the SITC 2016 Conference 46
Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist 47
Aug 08, 2016: Cancer Treatment Centers of America at Western Regional Medical Center is the first site in the world for new investigational anti-cancer treatment 48
Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing 49
Jun 01, 2016: Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints 49
Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA 49
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-170 and PD-L1/TIM-3 Antagonist at AACR Annual Meeting 50
Nov 08, 2015: Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA Program at AACR-NCI-EORTC International Conference 50
Nov 02, 2015: Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference 50
Oct 19, 2015: Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 19
Pipeline by BeiGene Ltd, H2 2017 19
Pipeline by Eli Lilly and Co, H2 2017 20
Pipeline by Enumeral Biomedical Holdings Inc, H2 2017 20
Pipeline by Incyte Corp, H2 2017 21
Pipeline by Interprotein Corp, H2 2017 21
Pipeline by Jounce Therapeutics Inc, H2 2017 22
Pipeline by Merus NV, H2 2017 22
Pipeline by Novartis AG, H2 2017 23
Pipeline by Sorrento Therapeutics Inc, H2 2017 23
Pipeline by Sutro Biopharma Inc, H2 2017 24
Pipeline by Tesaro Inc, H2 2017 24
Pipeline by Trellis Bioscience Inc, H2 2017 24
Dormant Projects, H2 2017 44

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 15
Number of Products by Stage and Routes of Administration, H2 2017 15
Number of Products by Molecule Types, H2 2017 17
Number of Products by Stage and Molecule Types, H2 2017 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *